These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25215607)

  • 1. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis.
    Cao JX; Zhang XY; Liu JL; Li D; Li JL; Liu YS; Wang M; Xu BL; Wang HB; Wang ZX
    PLoS One; 2014; 9(9):e107173. PubMed ID: 25215607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
    Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P
    Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
    Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
    Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
    Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
    J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.
    Lasky JL; Panosyan EH; Plant A; Davidson T; Yong WH; Prins RM; Liau LM; Moore TB
    Anticancer Res; 2013 May; 33(5):2047-56. PubMed ID: 23645755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
    Zhu X; Lu C; Xiao B; Qiao J; Sun Y
    J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials.
    Artene SA; Turcu-Stiolica A; Ciurea ME; Folcuti C; Tataranu LG; Alexandru O; Purcaru OS; Tache DE; Boldeanu MV; Silosi C; Dricu A
    Sci Rep; 2018 Aug; 8(1):11800. PubMed ID: 30087385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
    Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
    BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells.
    Parajuli P; Mathupala S; Sloan AE
    Neurosurgery; 2004 Nov; 55(5):1194-204. PubMed ID: 15509326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis.
    Wang ZX; Cao JX; Wang M; Li D; Cui YX; Zhang XY; Liu JL; Li JL
    Cytotherapy; 2014 Jul; 16(7):934-45. PubMed ID: 24794183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model.
    Kim JW; Kane JR; Panek WK; Young JS; Rashidi A; Yu D; Kanojia D; Hasan T; Miska J; Gómez-Lim MA; Ulasov IV; Balyasnikova IV; Ahmed AU; Wainwright DA; Lesniak MS
    Neurotherapeutics; 2018 Oct; 15(4):1127-1138. PubMed ID: 30027430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
    Jouanneau E; Poujol D; Gulia S; Le Mercier I; Blay JY; Belin MF; Puisieux I
    Cancer Immunol Immunother; 2006 Mar; 55(3):254-67. PubMed ID: 16133115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.
    Lin M; Liang S; Jiang F; Xu J; Zhu W; Qian W; Hu Y; Zhou Z; Chen J; Niu L; Xu K; Lv Y
    Immunol Lett; 2017 Mar; 183():37-43. PubMed ID: 28143792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.
    Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N
    Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
    Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
    Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of interferon-alpha-induced dendritic cells in the therapy of patients with malignant brain gliomas.
    Leplina OY; Stupak VV; Kozlov YP; Pendyurin IV; Nikonov SD; Tikhonova MA; Sycheva NV; Ostanin AA; Chernykh ER
    Bull Exp Biol Med; 2007 Apr; 143(4):528-34. PubMed ID: 18214316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
    Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
    Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ dendritic cell vaccination for the treatment of glioma and literature review.
    Li M; Han S; Shi X
    Tumour Biol; 2016 Feb; 37(2):1797-801. PubMed ID: 26318301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.